NEW HEMOFARM PREPARATIONS TO APPEAR SOON
NEW HEMOFARM PREPARATIONS TO APPEAR SOON
NEW HEMOFARM PREPARATIONS TO APPEAR SOON
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
mental state and covers stress in the life of the individual, manner of reaction to stress and ability to relax and enjoy spare<br />
time – said Dr. Đurić.<br />
Following these extremely interesting lectures, an award game was organized, and the socializing and discussions<br />
continued with a cocktail party for the occasion. (Prepared by: NČD with expert consultation by D. Đurić)<br />
PRILINDA IN FOCUS<br />
The workshop Prilinda in Focus was held in the club of the General Hospital in Šabac end of September, in which case<br />
presentations were made, reported Hemofarm Press, Savo Milošević, an associate in the Skill Team in the West Balkans.<br />
Three interesting lectures were held in the course of this workshop: Proton Pump Inhibitors in Modern Clinical Practice (doc.<br />
Dr. Miloš Bjelović, Institute for Digestive System Diseases, of the Clinical Center in Serbia), Decrease of risks in<br />
Cardiovascular Patients (case study) – Prilinda in Focus (prof. Dr. Biljana Obrenović – Kirćanski, Institute for Cardiovascular<br />
Diseases of the Clinical Center of Serbia) and HemofarmLogica –A Logical Therapeutic Choice for your Patient (dr.<br />
Ljiljana Ašković, Hemofarm A.D.).<br />
The workshop was conceived in such a manner that two cases were presented – administration of Prilinda and Tulip in<br />
primary prevention, in the case of high risk patients and a case of acute myocardial infarct - administration of Prilinda and<br />
Tulip in secondary prevention.<br />
This way of promotion gives the possibility of therapeutic connection of the HemofarmcardioLogica preparations, where<br />
the preparation dosage is presented through a real case, indications through mention of studies and anticipated benefits<br />
for patients are given.<br />
80 doctors of general medicine, internists, cardiologists and pharmacists attended the gathering in Šabac. They expressed<br />
a particular interest through a questionnaire in cases from practice, medicament status, interreactions and the therapeutic<br />
scope of Prilinda.<br />
According to Milošević there will soon be a couple of more similar workshops, this time in Loznica, Smederevo and<br />
Smederevska Palanka.<br />
Lectures in the form of workshops in all major centers are planned for October and November.<br />
THE NEZAVISNE NOVINE (INDEPENDENT PAPER) DELEGATION VISITS <strong>HEMOFARM</strong><br />
ACKNOWLEDGEMENT OF SUCCESSFUL COOPERATION<br />
The delegation of the company Nezavisne novine headed by the advisor to the director Neven Kopanja and the<br />
marketing director Sanja Blagojević, visited our plant in Banjaluka end of September.<br />
Director Aleksandar Veselinović, marketing manager of the region Dr. Saša Urošević, production chief Sonja Miličević and<br />
the expert associate for public relations Aleksandar Đurić were hosts to the guests and long term business partners from<br />
Nezavisne novine.<br />
The guests had an opportunity to get acquainted with the production process of the medicaments and to convey to the<br />
public the well-known facts, that high quality medicaments in accordance with world standars are produced in Hemofarm<br />
in Banjaluka, a fact supported by the certificates which have been given to Hemofarm Banjaluka.<br />
Following the introduction in which he greeted the guests and thanked them for their visit, director Veselinović pointed out in<br />
particular the obstructions in the establishment of a uniform market of medicaments in Bosnia and Hercegovina which are<br />
manifested by fact that the law on medicaments has not been passed yet on the level of Bosnia and Hercegovina.<br />
It is unbelievable that Hemofarm, although we are registered in Banjaluka, is not treated as a local producer of<br />
medicaments in the Bosnia and Hercegvina federation. It is absurd that we place our medicaments on the markets of EU,<br />
Asia and Africa and cannot do so in the other entity of the same country – pointed out Veselinović.